| Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non … ET Overton, G Richmond, G Rizzardini, H Jaeger, C Orrell, F Nagimova, ... The Lancet 396 (10267), 1994-2005, 2020 | 233 | 2020 |
| Evaluation of individual and ensemble probabilistic forecasts of COVID-19 mortality in the United States EY Cramer, EL Ray, VK Lopez, J Bracher, A Brennen, ... Proceedings of the National Academy of Sciences 119 (15), e2113561119, 2022 | 164 | 2022 |
| Vapor pressures of the polybrominated diphenyl ethers A Wong, YD Lei, M Alaee, F Wania Journal of Chemical & Engineering Data 46 (2), 239-242, 2001 | 162 | 2001 |
| Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies A Wong, TJ Marrie, S Garg, JD Kellner, GJ Tyrrell, SPAT Group Epidemiology & Infection 138 (12), 1804-1810, 2010 | 106 | 2010 |
| Efficacy and safety of bepirovirsen in chronic hepatitis B infection MF Yuen, SG Lim, R Plesniak, K Tsuji, HLA Janssen, C Pojoga, A Gadano, ... New England Journal of Medicine 387 (21), 1957-1968, 2022 | 91 | 2022 |
| Welders are at increased risk for invasive pneumococcal disease A Wong, TJ Marrie, S Garg, JD Kellner, GJ Tyrrell, SPAT Group International Journal of Infectious Diseases 14 (9), e796-e799, 2010 | 66 | 2010 |
| Disparities in direct acting antivirals uptake in HIV‐hepatitis C co‐infected populations in Canada S Saeed, EC Strumpf, EEM Moodie, J Young, R Nitulescu, J Cox, A Wong, ... Journal of the International AIDS Society 20 (3), e25013, 2017 | 64 | 2017 |
| Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept ML Ramien, A Wong, JS Keystone Clinical Infectious Diseases 52 (5), e133-e135, 2011 | 61 | 2011 |
| The Canadian HIV and aging cohort study-determinants of increased risk of cardio-vascular diseases in HIV-infected individuals: rationale and study protocol M Durand, C Chartrand-Lefebvre, JG Baril, S Trottier, B Trottier, M Harris, ... BMC infectious diseases 17, 1-10, 2017 | 56 | 2017 |
| Eliminating structural barriers: the impact of unrestricted access on hepatitis C treatment uptake among people living with human immunodeficiency virus S Saeed, E Strumpf, EEM Moodie, L Wong, J Cox, S Walmsley, M Tyndall, ... Clinical Infectious Diseases 71 (2), 363-371, 2020 | 44 | 2020 |
| CIHR Canadian HIV trials network coinfection and concurrent diseases core research group: 2016 updated Canadian HIV/hepatitis C adult guidelines for management and treatment M Hull, S Shafran, A Wong, A Tseng, P Giguère, L Barrett, S Haider, ... Canadian Journal of Infectious Diseases and Medical Microbiology 2016, 2016 | 36 | 2016 |
| Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open … ET Overton, G Richmond, G Rizzardini, A Thalme, PM Girard, A Wong, ... Clinical Infectious Diseases 76 (9), 1646-1654, 2023 | 31* | 2023 |
| Real‐world impact of direct acting antiviral therapy on health‐related quality of life in HIV/Hepatitis C co‐infected individuals S Saeed, EEM Moodie, E Strumpf, J Gill, A Wong, C Cooper, S Walmsley, ... Journal of viral hepatitis 25 (12), 1507-1514, 2018 | 30 | 2018 |
| Upregulation of IL-32 isoforms in virologically suppressed HIV-infected individuals: potential role in persistent inflammation and transcription from stable HIV-1 reservoirs SM Zaidan, L Leyre, R Bunet, E Larouche-Anctil, I Turcotte, M Sylla, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 82 (5), 503-513, 2019 | 25 | 2019 |
| Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV Network CS Coffin, A Ramji, CL Cooper, D Miles, KE Doucette, P Wong, E Tam, ... Canadian Medical Association Open Access Journal 7 (4), E610-E617, 2019 | 24 | 2019 |
| Hepatitis C virus (HCV) care in Canadian correctional facilities: Where are we and where do we need to be? N Kronfli, JA Buxton, L Jennings, F Kouyoumdjian, A Wong Canadian Liver Journal 2 (4), 171-183, 2019 | 22 | 2019 |
| Seeking shelter: homelessness and COVID-19 S Baral, A Bond, A Boozary, E Bruketa, N Elmi, D Freiheit, SM Ghosh, ... Facets 6 (1), 925-958, 2021 | 21 | 2021 |
| Effectiveness and renal safety of tenofovir alafenamide fumarate among chronic hepatitis B patients: real‐world study MS Farag, S Fung, E Tam, K Doucette, A Wong, A Ramji, B Conway, ... Journal of Viral Hepatitis 28 (6), 942-950, 2021 | 21 | 2021 |
| Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV‐HCV co‐infected patients in Canada N Kronfli, R Nitulescu, J Cox, EEM Moodie, A Wong, C Cooper, J Gill, ... African Journal of Reproduction and Gynaecological Endoscopy 21 (11), 2018 | 21 | 2018 |
| Extensive host immune adaptation in a concentrated North American HIV epidemic ZL Brumme, NN Kinloch, S Sanche, A Wong, E Martin, KD Cobarrubias, ... Aids 32 (14), 1927-1938, 2018 | 21 | 2018 |
Lisa BarrettDalhousie UniversityVerified email at nshealth.ca
